Biomay Ag

Phadia Ab

Biomay Produktions- Und Handelsgesellschaft M.b.h.

Other

Pharmacia Diagnostics Ab

Biomay Produktions- Und Handelsaktiengesellschaft

Viravaxx Ag

Pharmacia Ab

Pharmacia & Upjohn Ab

Worg Pharmaceuticals (zhejiang) Co., Ltd.

Viravaxx Gmbh

Biomay Biotechnik Produktions Und Handelsgesellschaft M.b.h.

Worg Pharmaceuticals Co., Ltd.

Valenta, Rudolf

Rudolf Valenta

Dietrich Kraft

Peter Valent

Susanne Vrtala

Wolfgang R Sperr

Hans Grönlund

Michael Breitenbach

Otto Scheiner

Sylvia Laffer

Helmut Rumpold

Birgit Linhart

Luca Vangelista

Margarete Focke-Tejkl

Kuan-Wei Chen

Karin Pettenburger

Annalisa Pastore

Monika Grote

Susanne Spitzauer

Heimo Breiteneder

Ines Swoboda

Katarzyna Niespodziana

Markus Susani

Tanja Ball

Sabine Stummfoll

Kerstin Westritschnig

Margit Weghofer

Milena Weber

Jonas Adriansson

Sabine Stumvoll

Katharina Blatt

Katharina Marth

Srinita Banerjee

Theresia Popow-Kraupp

Daniela Gallerano

Michael Duchene

Elopy N Sibanda

Paolo Colombo

Kenneth Roux

Dieter Blaas

Jonas Lidholm

Christof Ebner

Peter Steinberger

Ursula Wiedermann

Erik Högbom

Friedrich Horak

Pirjo Lehtonen

Marianne Van Hage

Wolfgang Sperr

Mirela Curin

Kenneth H Roux

Vera Mahler

Margarete Focke

Verena Niederberger

Asa Marknell Dewitt

Hans-Georg Eichler

Sabine Flicker

Hans Gr&ouml;nlund

Anna Twardosz

Petra Verdino

Johanna Edlmayr

Verena Niederberger-Leppin

Nikos Papadopoulos

Renate Reininger

Johanna Tinhofer

Claudia Constantin

Santiago Quirce

Angela Neubauer

Raffaela Campana

Anna Gieras

Hans Groenlund

Stefan Florian

Walter Keller

Maria-Theresia Krauth

Maria-Theresa Krauth

Margit Focke

Nadine Mothes

Marianne Van Hage-Hamsten

Alex Karlsson-Parra

Johan Roennelid

Sabine Stummvoll

Annalisa c/o Molecular Structure Div Pastore

Erik Hoegbom

Giovanni Duro

Domenico Geraci

Carolin Cornelius

The present invention relates to a fusion protein having formula (I)X&#x2212;Y&#x2212;X&#x2003;&#x2003;(I),wherein Xand Xcomprise each four to six allergen fragments or variants thereof fused to each other, wherein said allergen fragments are derived from at least two allergens of the genus, and wherein Y is a carrier protein.

Treatment and prevention of house dust mite allergies

The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ. ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample.

Method for detecting HIV-1-specific antibodies using clade C env polypeptides

The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample.

Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies

An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.

House dust mite allergen

The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.

Peptide carrier fusion proteins as allergy vaccines

The present invention relates to a pharmaceutical composition comprising at least one peptide consisting of a minimum of 8 and a maximum of 50 amino acid residues comprising amino acid residues 1 to 8 of a rhinovirus capsid protein selected from the group consisting of VP1, VP2, VP3 and VP4.

Method for diagnosing a rhinovirus infection

The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Vaccine carrier

The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.

Hypoallergenic polypeptides for the treatment of house dust mite allergy

The present invention relates to the field of IgE-mediated allergy, particularly occupational asthma such as bakers asthma. More specifically the invention relates to the identification of a novel wheat allergen and the use thereof in therapy and diagnosis of IgE-mediated allergy. Furthermore the present invention provides the use of known peptides and proteins in therapy and diagnosis. The invention also relates to methods for diagnosis and treatment of IgE-mediated allergy in mammals.

Wheat allergens

The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.

Hypoallergenic hybrid polypeptides for the treatment of allergy

Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Hypallergenic mosaic antigens and methods of making same

Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

Microparticles comprising carbohydrate beads covalently linked with allergen

Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

Non-anaphylactic forms of grass pollen Ph1 p 6 allergen and their use

The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics:

Compound for treatment of allergy and asthma

Growing community of inventors

Theresienfeld, Austria

Rudolf Valenta